Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Bowen

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Haematologica|July 20, 2004
NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q)Carrie Fidler, Fiona Watkins, David T Bowen, et al.
Blood|September 20, 2002
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitorsPanagiotis D Kottaridis, Rosemary E Gale, Stephen E Langabeer, et al.
Blood|September 23, 2015
Targeted sequencing identifies patients with preclinical MDS at high risk of disease progressionCatherine A Cargo, Nicola Rowbotham, Paul A Evans, et al.
Leukemia Research|July 24, 2012
Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192Marjorie Boissinot, Martyn Inman, Aiden Hempshall, et al.
Blood|December 7, 2002
CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplicationDavid T Bowen, Marion E Frew, Sara Rollinson, et al.
British Journal of Haematology|February 18, 2003
A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasiaSally B Killick, Ghulam Mufti, Jamie D Cavenagh, et al.
British Journal of Haematology|April 22, 2016
Impact of socioeconomic status on disease phenotype, genomic landscape and outcomes in myelodysplastic syndromesFrancesca Mastaglio, Khaled Bedair, Elli Papaemmanuil, et al.
Blood|May 16, 2009
Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndromeKen I Mills, Alexander Kohlmann, P Mickey Williams, et al.
Blood|June 14, 2005
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 yearsDavid T Bowen, Marion E Frew, Robert Hills, et al.
British Journal of Haematology|May 10, 2017
Telomere length is an independent prognostic marker in MDS but not in de novo AMLJenna Williams, Nicole H Heppel, Bethan Britt-Compton, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Haematologica|July 20, 2004
NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q)Carrie Fidler, Fiona Watkins, David T Bowen, et al.
Blood|September 20, 2002
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitorsPanagiotis D Kottaridis, Rosemary E Gale, Stephen E Langabeer, et al.
Blood|September 23, 2015
Targeted sequencing identifies patients with preclinical MDS at high risk of disease progressionCatherine A Cargo, Nicola Rowbotham, Paul A Evans, et al.
Leukemia Research|July 24, 2012
Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192Marjorie Boissinot, Martyn Inman, Aiden Hempshall, et al.
Blood|December 7, 2002
CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplicationDavid T Bowen, Marion E Frew, Sara Rollinson, et al.
British Journal of Haematology|February 18, 2003
A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasiaSally B Killick, Ghulam Mufti, Jamie D Cavenagh, et al.
British Journal of Haematology|April 22, 2016
Impact of socioeconomic status on disease phenotype, genomic landscape and outcomes in myelodysplastic syndromesFrancesca Mastaglio, Khaled Bedair, Elli Papaemmanuil, et al.
Blood|May 16, 2009
Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndromeKen I Mills, Alexander Kohlmann, P Mickey Williams, et al.
Blood|June 14, 2005
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 yearsDavid T Bowen, Marion E Frew, Robert Hills, et al.
British Journal of Haematology|May 10, 2017
Telomere length is an independent prognostic marker in MDS but not in de novo AMLJenna Williams, Nicole H Heppel, Bethan Britt-Compton, et al.
Pageof 3